The Experts below are selected from a list of 6414 Experts worldwide ranked by ideXlab platform
Jon D. Levine - One of the best experts on this subject based on the ideXlab platform.
-
Hyperalgesic priming (type II) induced by repeated opioid exposure: maintenance mechanisms.
Pain, 2017Co-Authors: Dioneia Araldi, Luiz F Ferrari, Jon D. LevineAbstract:We previously developed a model of opioid-induced neuroplasticity in the peripheral terminal of the nociceptor that could contribute to opioid-induced hyperalgesia, type II hyperalgesic priming. Repeated administration of mu-opioid receptor (MOR) agonists, such as DAMGO, at the peripheral terminal of the nociceptor, induces long-lasting plasticity expressed, prototypically as opioid-induced hyperalgesia and prolongation of prostaglandin E2-induced hyperalgesia. In this study, we evaluated the mechanisms involved in the maintenance of type II priming. Opioid receptor antagonist, naloxone, induced hyperalgesia in DAMGO-primed paws. When repeatedly injected, naloxone-induced hyperalgesia, and hyperalgesic priming, supporting the suggestion that maintenance of priming involves changes in MOR signaling. However, the knockdown of MOR with oligodeoxynucleotide antisense did not reverse priming. Mitogen-activated protein kinase and focal adhesion kinase, which are involved in the Src signaling pathway, previously implicated in type II priming, also inhibited the expression, but not maintenance of priming. However, when Src and mitogen-activated protein kinase inhibitors were coadministered, type II priming was reversed, in male rats. A second model of priming, latent sensitization, induced by complete Freund's adjuvant was also reversed, in males. In females, the inhibitor combination was only able to inhibit the expression and maintenance of DAMGO-induced priming when knockdown of G-protein-coupled estrogen receptor 30 (GPR30) in the nociceptor was performed. These findings demonstrate that the maintenance of DAMGO-induced type II priming, and latent sensitization is mediated by an interaction between, Src and MAP kinases, which in females is GPR30 dependent.
-
Dissociation of tolerance and dependence for opioid peripheral antinociception in rats.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 1997Co-Authors: K. O. Aley, Jon D. LevineAbstract:Repeated peripheral administration of the μ-opioid agonist [d-Ala 2 , N -Me-Phe 4 ,gly 5 -ol] enkephalin (DAMGO) produces acute tolerance and dependence on its peripheral antinociceptive effect against prostaglandin E 2 (PGE 2 )-induced mechanical hyperalgesia. In this study we evaluated the roles of protein kinase C (PKC) and nitric oxide (NO) in the development of this tolerance and dependence. Repeated administration of PKC inhibitors chelerythrine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride with DAMGO did not alter the tolerance to DAMGO; however, dependence (defined as naloxone-induced withdrawal hyperalgesia) was blocked. Repeated administration of N -( n -heptyl)-5-chloro-1-naphthalenesulfonamide, a PKC activator, which alone did not produce tolerance, mimicked the dependence produced by DAMGO. Repeated administration of the NO synthase inhibitor N G -methyl-l-arginine with DAMGO blocked the development of tolerance to DAMGO but had no effect on the development of dependence. Repeated administration of l-arginine, a NO precursor, mimicked tolerance produced by repeated administration of DAMGO (i.e., the antinociceptive effect of DAMGO was lost); however, l-arginine did not mimic dependence. These findings suggest that the development of acute tolerance and dependence on the peripheral antinociceptive effects of DAMGO have different, dissociable mechanisms. Specifically, PKC is involved in development of μ-opioid dependence, whereas the NO signaling system is involved in the development of μ-opioid tolerance.
-
DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro.
Neuroscience letters, 1996Co-Authors: Michael S. Gold, Jon D. LevineAbstract:We have tested the hypothesis that the mu-opioid agonist, [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin (DAMGO), inhibits prostaglandin E2 (PGE2)-induced modulation of a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R INa) in putative nociceptors in vitro. Patch-clamp electrophysiological techniques were used on cultured dorsal root ganglion neurons from the adult rat. PGE2 (1 microM) induced a 103 +/- 22.8% increase in peak TTX-R INa. The PGE2-induced increase in TTX-R INa in the presence of 1 microM DAMGO (24.9 +/- 7.7%), was significantly less than that induced by PGE2 alone. In contrast, when DAMGO was applied after PGE2, PGE2-induced increase in TTX-R INa (85.3 +/- 19.6%) was not significantly different than the increase in the current induced by PGE2 alone. Preapplication of naloxone (10 microM) blocked DAMGO-induced inhibition of the PGE2-induced increase in TTX-R INa. DAMGO, alone, had no effect on peak TTX-R INa (1.4 +/- 1.5% of baseline). Our observation that DAMGO prevents PGE2-induced potentiation of TTX-R INa is consistent with the suggestion that modulation of TTX-R INa underlies the hyperalgesic agent-induced increase in the excitability of nociceptors associated with sensitization and hyperalgesia. Furthermore, our data suggest that inhibition of hyperalgesic agent induced modulation of TTX-R INa may be a novel mechanism underlying opioid-induced antinociception.
-
DAMGO inhibits prostaglandin e2 induced potentiation of a ttx resistant na current in rat sensory neurons in vitro
Neuroscience Letters, 1996Co-Authors: Michael S. Gold, Jon D. LevineAbstract:We have tested the hypothesis that the mu-opioid agonist, [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin (DAMGO), inhibits prostaglandin E2 (PGE2)-induced modulation of a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R INa) in putative nociceptors in vitro. Patch-clamp electrophysiological techniques were used on cultured dorsal root ganglion neurons from the adult rat. PGE2 (1 microM) induced a 103 +/- 22.8% increase in peak TTX-R INa. The PGE2-induced increase in TTX-R INa in the presence of 1 microM DAMGO (24.9 +/- 7.7%), was significantly less than that induced by PGE2 alone. In contrast, when DAMGO was applied after PGE2, PGE2-induced increase in TTX-R INa (85.3 +/- 19.6%) was not significantly different than the increase in the current induced by PGE2 alone. Preapplication of naloxone (10 microM) blocked DAMGO-induced inhibition of the PGE2-induced increase in TTX-R INa. DAMGO, alone, had no effect on peak TTX-R INa (1.4 +/- 1.5% of baseline). Our observation that DAMGO prevents PGE2-induced potentiation of TTX-R INa is consistent with the suggestion that modulation of TTX-R INa underlies the hyperalgesic agent-induced increase in the excitability of nociceptors associated with sensitization and hyperalgesia. Furthermore, our data suggest that inhibition of hyperalgesic agent induced modulation of TTX-R INa may be a novel mechanism underlying opioid-induced antinociception.
Michael S. Gold - One of the best experts on this subject based on the ideXlab platform.
-
DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro.
Neuroscience letters, 1996Co-Authors: Michael S. Gold, Jon D. LevineAbstract:We have tested the hypothesis that the mu-opioid agonist, [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin (DAMGO), inhibits prostaglandin E2 (PGE2)-induced modulation of a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R INa) in putative nociceptors in vitro. Patch-clamp electrophysiological techniques were used on cultured dorsal root ganglion neurons from the adult rat. PGE2 (1 microM) induced a 103 +/- 22.8% increase in peak TTX-R INa. The PGE2-induced increase in TTX-R INa in the presence of 1 microM DAMGO (24.9 +/- 7.7%), was significantly less than that induced by PGE2 alone. In contrast, when DAMGO was applied after PGE2, PGE2-induced increase in TTX-R INa (85.3 +/- 19.6%) was not significantly different than the increase in the current induced by PGE2 alone. Preapplication of naloxone (10 microM) blocked DAMGO-induced inhibition of the PGE2-induced increase in TTX-R INa. DAMGO, alone, had no effect on peak TTX-R INa (1.4 +/- 1.5% of baseline). Our observation that DAMGO prevents PGE2-induced potentiation of TTX-R INa is consistent with the suggestion that modulation of TTX-R INa underlies the hyperalgesic agent-induced increase in the excitability of nociceptors associated with sensitization and hyperalgesia. Furthermore, our data suggest that inhibition of hyperalgesic agent induced modulation of TTX-R INa may be a novel mechanism underlying opioid-induced antinociception.
-
DAMGO inhibits prostaglandin e2 induced potentiation of a ttx resistant na current in rat sensory neurons in vitro
Neuroscience Letters, 1996Co-Authors: Michael S. Gold, Jon D. LevineAbstract:We have tested the hypothesis that the mu-opioid agonist, [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin (DAMGO), inhibits prostaglandin E2 (PGE2)-induced modulation of a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R INa) in putative nociceptors in vitro. Patch-clamp electrophysiological techniques were used on cultured dorsal root ganglion neurons from the adult rat. PGE2 (1 microM) induced a 103 +/- 22.8% increase in peak TTX-R INa. The PGE2-induced increase in TTX-R INa in the presence of 1 microM DAMGO (24.9 +/- 7.7%), was significantly less than that induced by PGE2 alone. In contrast, when DAMGO was applied after PGE2, PGE2-induced increase in TTX-R INa (85.3 +/- 19.6%) was not significantly different than the increase in the current induced by PGE2 alone. Preapplication of naloxone (10 microM) blocked DAMGO-induced inhibition of the PGE2-induced increase in TTX-R INa. DAMGO, alone, had no effect on peak TTX-R INa (1.4 +/- 1.5% of baseline). Our observation that DAMGO prevents PGE2-induced potentiation of TTX-R INa is consistent with the suggestion that modulation of TTX-R INa underlies the hyperalgesic agent-induced increase in the excitability of nociceptors associated with sensitization and hyperalgesia. Furthermore, our data suggest that inhibition of hyperalgesic agent induced modulation of TTX-R INa may be a novel mechanism underlying opioid-induced antinociception.
Susanna Fürst - One of the best experts on this subject based on the ideXlab platform.
-
Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
Brain research bulletin, 2012Co-Authors: Apolka Szentirmay, Kornél Király, N. Lenkey, Erzsébet Lackó, Mahmoud Al-khrasani, T. Friedmann, Julia Timár, Susanna Gyarmati, Géza Tóth, Susanna FürstAbstract:Since the discovery of opioid receptor dimers their possible roles in opioid actions were intensively investigated. Here we suggest a mechanism that may involve the μ-δ opioid heterodimers. The exact role of δ opioid receptors in antinociception and in the development of opioid tolerance is still unclear. While receptor up-regulation can be observed during the development of opioid tolerance no μ receptor down-regulation could be detected within five days. In our present work we investigated how the selective δ opioid receptor agonists and antagonists influence the antinociceptive effect of the selective μ receptor agonist DAMGO in naive and morphine-tolerant mice. We treated male NMRI mice with 200 μmol/kg subcutaneous (s.c.) morphine twice daily for three days. On the fourth day we measured the antinociceptive effect of DAMGO alone and combined with delta ligands: DPDPE, deltorphin II (agonists), TIPP and TICPψ (antagonists), respectively, administered intrathecally (i.t.) in mouse tail-flick test. In naive control mice none of the δ ligands caused significant changes in the antinociceptive action of DAMGO. The treatment with s.c. morphine resulted in approximately four-fold tolerance to i.t. DAMGO, i.e. the ED₅₀ value of DAMGO was four times as high as in naive mice. 500 and 1000 pmol/mouse of the δ₁ selective agonist DPDPE enhanced the tolerance to DAMGO while 1000 pmol/mouse of the δ₂ selective agonist deltorphin II did not influence the degree of tolerance. However, both δ antagonists TIPP and TICPψ potentiated the antinociceptive effect of i.t. DAMGO, thus they restored the potency of DAMGO to the control level. The inhibitory action of DPDPE against the antinociceptive effect of DAMGO could be antagonized by TIPP and TICPψ. We hypothesize that during the development of morphine tolerance the formation of μδ heterodimers may contribute to the spinal opioid tolerance. δ ligands may affect the dimer formation differently. Those, like DPDPE may facilitate the dimer formation hence inhibit the antinociceptive effect of DAMGO by causing virtual μ receptor down-regulation. Ligands that do not affect the dimer formation do not influence antinociception either but ligands with the presumed capability of disconnecting the dimers may decrease the spinal tolerance to DAMGO.
-
The peripheral antinociceptive effect of DAMGO and 6β-glycine-substituted 14-O-methyloxymorphone (HS-731) after systemic administration in a mouse visceral pain model
BMC Pharmacology, 2007Co-Authors: Mahmoud Al-khrasani, Kornél Király, T. Friedmann, Mariana Spetea, Pál Riba, Helmut Schmidhammer, Susanna FürstAbstract:Inhibition of nociception through activation of peripheral μ opioid receptors (MOR) avoiding the central adverse effects of opioids has added a new possibility to manage pain control. Here we report the antinociceptive effects of the peripherally restricted MOR agonist HS-731, the peptide DAMGO, and morphine in the writhing test in mice. S.c. and i.c.v. HS-731 dose-dependently and completely inhibited writhing, being 24–598 times more potent than the two MOR-selective agonists DAMGO and morphine. However, extremely high s.c./i.c.v. potency ratios were calculated for HS-731 and DAMGO and much lower for morphine. Remarkably, a long duration of action was induced by HS-731 and much shorter by morphine and DAMGO. The antinociceptive effects of systemic opioids were reversed by s.c. naloxone while i.c.v. administration of the MOR selective antagonist CTAP significantly abolished the antinociceptive effect of s.c. morphine but completely failed to antagonize the effects of systemic HS-731 or DAMGO. In addition, in the rat vas deferens HS-731 and DAMGO, but not morphine, showed high intrinsic efficacy and naltrexone-sensitive agonist response at MOR by depressing electrically-evoked contractions of this organ. These data demonstrate that the selectivity and high efficacy of HS-731 and DAMGO at peripheral MOR as well as their inability to cross the blood brain barrier are a cornerstone for producing peripheral antinociception after systemic administration.
-
DAMGO and 6β-glycine substituted 14 -O -methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens
Brain research bulletin, 2007Co-Authors: Mahmoud Al-khrasani, Kornél Király, T. Friedmann, Mariana Spetea, Pál Riba, Helmut Schmidhammer, Susanna FürstAbstract:Peripheral micro-opioid receptors (MOR) have emerged as important components of inhibitory nociceptive pathways. Here, the antinociceptive effects of MOR agonists, the 6beta-glycine derivative of 14-O-methyloxymorphone (HS-731), DAMGO and morphine were evaluated in a mouse model of visceral pain. The abdominal acetic acid-induced writhing test was used to examine the peripheral, preemptive antinociceptive opioid action on visceral nociception. HS-731 administered subcutaneously (s.c.) or intracerebroventricularly (i.c.v.) dose-dependently and completely inhibited writhing, being 24-598-fold more potent, depending on the administration route, than two selective MOR agonists, the enkephalin analogue [D-Ala(2),N-Me-Phe(4),Gly-ol(5)]enkephalin (DAMGO) and morphine. A longer duration of action (2-3 h) was induced by HS-731 given before acetic acid, while shorter effect was produced by morphine (30-60 min) and DAMGO (30-45 min). The antinociceptive effects of systemic opioids were reversed by the s.c. opioid antagonist, naloxone. Blocking of central MOR by the selective MOR antagonist D-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH(2) (CTAP, i.c.v.) resulted in a significant reduction of antinociception of s.c. morphine, whereas it completely failed to antagonize the effects of systemic HS-731 or DAMGO. In in vitro studies, HS-731 and DAMGO, but not morphine showed high intrinsic efficacy, naltrexone-sensitive agonist effect at MOR of the rat vas deferens. These data demonstrate that selective activation of peripheral MOR by systemic s.c. HS-731 or DAMGO produces potent peripheral, preemptive visceral antinociception, while morphine's effects are mediated primarily through central mechanisms. Our findings support the role of peripheral MOR in the pathology of pain states involving sensitization of peripheral nociceptors.
Ping Zheng - One of the best experts on this subject based on the ideXlab platform.
-
DAMGO depresses inhibitory synaptic transmission via different downstream pathways of μ opioid receptors in ventral tegmental area and periaqueductal gray
Neuroscience, 2015Co-Authors: Wen Zhang, Hualan Yang, Jiaojiao Song, Ming Chen, Yi Dong, Bin Lai, Ping ZhengAbstract:Opioid-induced rewarding and motorstimulant effects are mediated by an increased activity of the ventral tegmental area (VTA) dopamine (DA) neurons. The excitatory mechanism of opioids on VTA-DA neurons has been proposed to be due to the depression of GABAergic synaptic transmission in VTA-DA neurons. However, how opioids depress GABAergic synaptic transmission in VTA-DA neurons remain to be studied. In the present study, we explored the mechanism of the inhibitory effect of [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin (DAMGO) on GABAergic synaptic transmission in VTA-DA neurons using multiple approaches and techniques. Our results showed that (1) DAMGO inhibits GABAergic inputs in VTA-DA neurons at presynaptic sites; (2) effect of DAMGO on GABAergic inputs in VTA-DA neurons is inhibited by potassium channel blocker 4-aminopyridine (4-AP) and Gi protein inhibitor N-ethylmaleimide (NEM); (3) phospholipase A2 (PLA2) does not mediate the effect of DAMGO on GABAergic inputs in VTA-DA neurons, but mediates it in the periaqueductal gray (PAG); (4) multiple downstream signaling molecules of μ receptors do not mediate the effect of DAMGO on GABAergic inputs in VTA-DA neurons. These results suggest that DAMGO depresses inhibitory synaptic transmission via μ receptor-Gi protein-Kv channel pathway in VTA-DA neurons, but via μ receptor-PLA2 pathway in PAG neurons.
-
Morphine and DAMGO produce an opposite effect on presynaptic glutamate release via different downstream pathways of μ opioid receptors in the basolateral amygdala
Neuropharmacology, 2014Co-Authors: Jinhui Yang, Hualan Yang, Jiaojiao Song, Ming Chen, Yi Dong, Ping ZhengAbstract:Increasing evidence demonstrates that different opioids, while acting μ opioid receptors, can activate distinct downstream responses, a phenomenon termed functional selectivity or biased agonism. The present study designed experiments to test whether the μ receptor agonist morphine and D-Ala(2), N-Me-Phe(4), Gly(5)-ol-enkephalin (DAMGO) had a different effect on presynaptic glutamate release in the basolateral amygdala (BLA) and whether this difference was due to their biased agonism at μ receptors. The results showed that DAMGO markedly decreased the frequency of sEPSCs in pyramidal cells of BLA. The concentration-dependence experiment showed that DAMGO dose-dependently decreased the frequency of sEPSCs. Morphine markedly increased the frequency of sEPSCs in pyramidal cells of BLA. The concentration-dependence experiment showed that morphine dose-dependently increased the frequency of sEPSCs. We also used PPF of EPSC as another indicator of presynaptic glutamate release to confirm the opposite effect of morphine and DAMGO on the glutamate release. Further mechanism studies showed that the opposite effect of morphine and DAMGO on the glutamate release was via the activation of μ receptors, but the downstream signaling pathways of μ receptors were different: DAMGO inhibited the glutamate release via μ receptor-Gi protein- PLA2-AA signaling pathway, whereas morphine promoted the glutamate release via μ receptor-Gi protein-PKC-ERK1/2-synapsin I signaling pathway.
Lee-yuan Liu-chen - One of the best experts on this subject based on the ideXlab platform.
-
Brain region‐ and sex‐specific alterations in DAMGO‐stimulated [35S]GTPγS binding in mice with Oprm1 A112G
Addiction biology, 2012Co-Authors: Yujun Wang, Peng Huang, Julie A. Blendy, Lee-yuan Liu-chenAbstract:The A118G single nucleotide polymorphism (SNP) of the human μ-opioid receptor (MOPR) gene (OPRM1) was associated with heightened dopamine release by alcohol intake, better treatment outcome for nicotine and alcohol addiction, and reduced analgesic responses to morphine. A mouse model that possesses the equivalent substitution (A112G) in the mouse MOPR gene (OPRM1) was generated to delineate the mechanisms of the impact of the SNP. Mice homozygous for the G112 allele (G/G) displayed lower morphine-induced antinociception than mice homozygous for the A112 allele (A/A), similar to the results in humans. In this study, we examined whether A112G SNP affected MOPR-mediated G protein activation in the mouse model. We compared A/A and G/G mice in the MOPR-selective agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO)-stimulated [(35) S]GTPγS binding in brain regions by autoradiography. When the data of males and females were combined, G/G mice exhibited lower DAMGO-stimulated [(35) S]GTPγS binding in the ventral tegmental area than A/A mice, in accord with the previously reported reduced morphine-induced hyperactivity and locomotor sensitization in G/G mice. In the nucleus accumbens (NAc) core, female G/G mice displayed lower DAMGO-stimulated [(35) S]GTPγS binding than female A/A mice, which is consistent with the previously reported deficiency in morphine-induced conditioned place preference in female G/G mice. In G/G mice, males showed higher DAMGO-stimulated [(35) S]GTPγS binding than females in the cingulate cortex, caudate putamen, NAc core, thalamus and amygdala. Thus, A112G SNP affects DAMGO-stimulated [(35) S]GTPγS binding in region- and sex-specific manners.
-
Functional role of the spatial proximity of Asp114(2.50) in TMH 2 and Asn332(7.49) in TMH 7 of the μ opioid receptor
FEBS Letters, 1999Co-Authors: Fatih Ozdener, Chonguang Chen, J. Kim De Riel, Harel Weinstein, Lee-yuan Liu-chenAbstract:We examined whether a proposed spatial proximity between Asp114(2.50) and Asn332(7.49) affected the functional properties of the μ opioid receptor. The D114(2.50)N mutant had reduced binding affinities for morphine, DAMGO and CTAP, but not for naloxone and [3H]diprenorphine; this mutation also abolished agonist-induced increase in [35S]GTPγS binding. The N332(7.49)D mutation eliminated detectable binding of either [3H]diprenorphine or [3H]DAMGO. The combined D114(2.50)N-N332(7.49)D mutation restored high affinity binding for [3H]diprenorphine, CTAP and naloxone, and restored partially the binding affinities, potencies and efficacies of morphine and DAMGO. Thus, reciprocal mutations of Asp114(2.50) and Asn332(7.49) compensate for the detrimental effects of the single mutations, indicating that the residues are adjacent in space and that their chemical functionalities are important for ligand binding and receptor activation.
